[go: up one dir, main page]

WO2010075424A3 - Compositions et procédés de réduction de gènes procaryotes - Google Patents

Compositions et procédés de réduction de gènes procaryotes Download PDF

Info

Publication number
WO2010075424A3
WO2010075424A3 PCT/US2009/069258 US2009069258W WO2010075424A3 WO 2010075424 A3 WO2010075424 A3 WO 2010075424A3 US 2009069258 W US2009069258 W US 2009069258W WO 2010075424 A3 WO2010075424 A3 WO 2010075424A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
prokaryotic genes
crispr
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/069258
Other languages
English (en)
Other versions
WO2010075424A2 (fr
Inventor
Victor Kunin
Susan Yilmaz
Rotem Sorek
Philip Hugenholtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2010075424A2 publication Critical patent/WO2010075424A2/fr
Publication of WO2010075424A3 publication Critical patent/WO2010075424A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un polynucléotide isolé qui comprend une séquence d'acide nucléique à série CRISPR (clustered regularly interspaced short palindromic repeat) où au moins un espaceur de la CRISPR est suffisamment complémentaire d'une partie d'au moins un gène procaryote afin de réduire l'expression du gène procaryote. La présente invention concerne également des utilisations des polynucléotides et de compositions pharmaceutiques qui comprennent les polynucléotides.
PCT/US2009/069258 2008-12-22 2009-12-22 Compositions et procédés de réduction de gènes procaryotes Ceased WO2010075424A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19374208P 2008-12-22 2008-12-22
US61/193,742 2008-12-22

Publications (2)

Publication Number Publication Date
WO2010075424A2 WO2010075424A2 (fr) 2010-07-01
WO2010075424A3 true WO2010075424A3 (fr) 2010-09-02

Family

ID=42288422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/069258 Ceased WO2010075424A2 (fr) 2008-12-22 2009-12-22 Compositions et procédés de réduction de gènes procaryotes

Country Status (1)

Country Link
WO (1) WO2010075424A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US10765740B2 (en) 2016-06-05 2020-09-08 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10920222B2 (en) 2018-04-30 2021-02-16 Snipr Biome Aps Treating and preventing microbial infections
US11147830B2 (en) 2015-05-06 2021-10-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113376A1 (en) * 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
EP2841572B1 (fr) 2012-04-27 2019-06-19 Duke University Correction génétique de gènes ayant subi une mutation
US20160046961A1 (en) 2012-05-25 2016-02-18 Emmanuelle Charpentier Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
EP2928496B1 (fr) 2012-12-06 2019-10-09 Sigma Aldrich Co. LLC Modification et régulation du génome basées sur crispr
WO2014093479A1 (fr) * 2012-12-11 2014-06-19 Montana State University Contrôle de la régulation génétique guidé par arn crispr (répétitions palindromiques groupées, courtes régulièrement espacées )
JP2016501531A (ja) 2012-12-12 2016-01-21 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作および治療適用のための系、方法および組成物の送達、エンジニアリングおよび最適化
CA2894668A1 (fr) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Systemes de composants de crispr-cas, procedes et compositions pour la manipulation de sequences
WO2014093701A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
ES2701749T3 (es) 2012-12-12 2019-02-25 Broad Inst Inc Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
EP3919505B1 (fr) 2013-01-16 2023-08-30 Emory University Utilisations des complexes d'acide nucléique cas9
ES2901396T3 (es) 2013-03-14 2022-03-22 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP3778899A1 (fr) * 2013-05-22 2021-02-17 Northwestern University Clivage de l'adn orienté vers arn et édition génétique par l'enzyme cas9 provenant de neisseria meningitidis
EP3011030B1 (fr) 2013-06-17 2023-11-08 The Broad Institute, Inc. Systèmes, procédés et compositions à double nickase crispr-cas optimisés, pour la manipulation de séquences
EP3725885A1 (fr) 2013-06-17 2020-10-21 The Broad Institute, Inc. Génomique fonctionnelle utilisant des systèmes crispr-cas, compositions, procédés, cribles et applications de ces systèmes
SG10201710487VA (en) 2013-06-17 2018-01-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components
WO2014204724A1 (fr) 2013-06-17 2014-12-24 The Broad Institute Inc. Administration, modification et optimisation de systèmes guides tandems, méthodes et compositions pour la manipulation de séquence
EP3825406A1 (fr) 2013-06-17 2021-05-26 The Broad Institute Inc. Administration et utilisation de systèmes crispr-cas, vecteurs et compositions pour le ciblage et le traitement du foie
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
DK3041498T3 (da) 2013-09-05 2022-05-09 Massachusetts Inst Technology Afstemning af mikrobielle populationer med programmerbare nukleaser
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
US10767156B2 (en) 2013-10-24 2020-09-08 Yeda Research And Development Co., Ltd. Polynucleotides encoding BREX system polypeptides and methods of using same
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
KR102523466B1 (ko) 2013-11-07 2023-04-20 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
US20150132263A1 (en) * 2013-11-11 2015-05-14 Radiant Genomics, Inc. Compositions and methods for targeted gene disruption in prokaryotes
WO2015089462A1 (fr) 2013-12-12 2015-06-18 The Broad Institute Inc. Distribution, utilisation et applications thérapeutiques des systèmes crispr-cas et compositions pour l'édition du génome
WO2015089364A1 (fr) 2013-12-12 2015-06-18 The Broad Institute Inc. Structure cristalline d'un système crispr-cas, et ses utilisations
EP3080271B1 (fr) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systèmes, procédés et compositions pour manipulation de séquences avec systèmes crispr-cas fonctionnels optimisés
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
KR20160089530A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒ­ｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용
BR112016013547A2 (pt) 2013-12-12 2017-10-03 Broad Inst Inc Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
EP4219699A1 (fr) 2013-12-12 2023-08-02 The Broad Institute, Inc. Ingénierie de systèmes, procédés et compositions de guide optimisées avec de nouvelles architectures pour la manipulation de séquence
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
ES2827279T3 (es) * 2014-04-14 2021-05-20 Nemesis Bioscience Ltd Terapéutico
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11071289B2 (en) 2014-08-14 2021-07-27 Biocytogen Boston Corp DNA knock-in system
WO2016033298A1 (fr) 2014-08-28 2016-03-03 North Carolina State University Nouvelles protéines cas9 et éléments de guidage pour le ciblage de l'adn et l'édition du génome
US10370673B2 (en) 2014-09-26 2019-08-06 Purecircle Sdn Bhd Single nucleotide polymorphism (SNP) markers for stevia
JP6860483B2 (ja) 2014-11-26 2021-04-14 テクノロジー イノベーション モメンタム ファンド（イスラエル）リミテッド パートナーシップＴｅｃｈｎｏｌｏｇｙ Ｉｎｎｏｖａｔｉｏｎ Ｍｏｍｅｎｔｕｍ Ｆｕｎｄ（ｉｓｒａｅｌ）Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ 細菌遺伝子の標的化削減
EP3985115A1 (fr) 2014-12-12 2022-04-20 The Broad Institute, Inc. Arn guides protégés (pgrnas)
WO2016106236A1 (fr) * 2014-12-23 2016-06-30 The Broad Institute Inc. Système de ciblage d'arn
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
CN108026536A (zh) 2015-05-29 2018-05-11 北卡罗来纳州立大学 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
ES2960226T3 (es) 2015-06-15 2024-03-01 Univ North Carolina State Métodos y composiciones para la administración eficiente de ácidos nucleicos y antimicrobianos basados en ARN
RU2752834C2 (ru) 2015-06-18 2021-08-09 Те Брод Инститьют, Инк. Мутации фермента crispr, уменьшающие нецелевые эффекты
WO2016205759A1 (fr) 2015-06-18 2016-12-22 The Broad Institute Inc. Modification et optimisation de systèmes, de méthodes, d'enzymes et d'échafaudages guides d'orthologues de cas9 et variant pour la manipulation de séquences
GB201514510D0 (en) 2015-08-14 2015-09-30 Nemesis Bioscience Ltd Delivery vehicle
WO2017058751A1 (fr) 2015-09-28 2017-04-06 North Carolina State University Méthodes et compositions pour agents antimicrobiens spécifiques d'une séquence
AU2016334225B2 (en) 2015-10-09 2022-11-10 Monsanto Technology Llc Novel RNA-guided nucleases and uses thereof
US11970710B2 (en) * 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
CA3002827A1 (fr) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Editeurs de nucleobases et leurs utilisations
EA201891317A3 (ru) 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
WO2017100376A2 (fr) 2015-12-07 2017-06-15 Zymergen, Inc. Promoteurs de corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
WO2017147278A1 (fr) 2016-02-25 2017-08-31 The Children's Medical Center Corporation Commutateur de classe personnalisé de gènes d'immunoglobuline dans un lymphome et un hybridome par la technologie crispr/cas9
EP3219799A1 (fr) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Expression sgrna crispr conditionnelle
EP3443081A4 (fr) 2016-04-13 2019-10-30 Duke University Répresseurs à base de crispr/cas9 pour inactiver des cibles géniques in vivo et procédés d'utilisation
NZ748874A (en) * 2016-05-01 2025-08-29 Neemo Inc Harnessing heterologous and endogenous crispr-cas machineries for efficient markerless genome editing in clostridium
IL295358B2 (en) 2016-06-02 2023-09-01 Sigma Aldrich Co Llc Use of programmable DNA-binding proteins to enhance targeted genome modification
WO2018005655A2 (fr) 2016-06-30 2018-01-04 Zymergen Inc. Procédés de génération d'une bibliothèque d'hémoglobines bactériennes et utilisations associées
EP3478845A4 (fr) 2016-06-30 2019-07-31 Zymergen, Inc. Procédés de production d'une banque de glucose perméase et utilisations associées
EP4275747A3 (fr) 2016-07-19 2024-01-24 Duke University Applications thérapeutiques de l'édition du génome fondée sur cpf1
KR102827276B1 (ko) 2016-08-03 2025-07-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (fr) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Éditeur de base cytosine à guanine
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP4623922A2 (fr) 2017-06-25 2025-10-01 SNIPR Technologies Limited Modification de populations microbiennes et modification de microbiote
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (fr) 2017-08-30 2019-07-18 President And Fellows Of Harvard College Éditeurs de bases à haut rendement comprenant une gam
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
US20190160120A1 (en) * 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
EP3724214A4 (fr) 2017-12-15 2021-09-01 The Broad Institute Inc. Systèmes et procédés de prédiction des résultats de la réparation en ingénierie génétique
WO2019226953A1 (fr) 2018-05-23 2019-11-28 The Broad Institute, Inc. Éditeurs de bases et leurs utilisations
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
WO2020072250A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant et utilisations de ce dernbier pour la modification du génome et la modification de l'expression
WO2020072248A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant
WO2020072254A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant et ses utilisations pour tuer des cellules cibles
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB2601617B (en) 2019-03-19 2024-02-21 Broad Inst Inc Methods and compositions for editing nucleotide sequences
EP3956349A1 (fr) 2019-04-17 2022-02-23 The Broad Institute, Inc. Éditeurs de base d'adénine présentant des effets hors cible réduits
EP4061153A4 (fr) * 2019-06-06 2023-05-10 Tata Consultancy Services Limited Système et méthode de lutte contre les infections par mycobacterium tuberculosis
WO2021072328A1 (fr) 2019-10-10 2021-04-15 The Broad Institute, Inc. Procédés et compositions pour le prime editing d'arn
WO2021138560A2 (fr) 2020-01-02 2021-07-08 The Trustees Of Columbia University In The City Of New York Activation transcriptionnelle de crispr-cas programmable et portable dans des bactéries
EP4146804A1 (fr) 2020-05-08 2023-03-15 The Broad Institute Inc. Méthodes et compositions d'édition simultanée des deux brins d'une séquence nucléotidique double brin cible
AU2023289696A1 (en) 2022-06-24 2025-01-16 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US7208317B2 (en) * 2002-05-02 2007-04-24 The University Of North Carolina At Chapel Hill In Vitro mutagenesis, phenotyping, and gene mapping
US20080124725A1 (en) * 2006-05-19 2008-05-29 Rodolphe Barrangou Tagged microorganisms and methods of tagging

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208317B2 (en) * 2002-05-02 2007-04-24 The University Of North Carolina At Chapel Hill In Vitro mutagenesis, phenotyping, and gene mapping
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US20080124725A1 (en) * 2006-05-19 2008-05-29 Rodolphe Barrangou Tagged microorganisms and methods of tagging

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROUNS ET AL.: "Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes", SCIENCE, vol. 321, no. 5891, 15 August 2008 (2008-08-15), pages 960 - 964 *
HALE ET AL.: "Prokaryotic silencing (psi)RNAs in Pyrococcus furiosus.", RNA, vol. 14, no. 12, 2008, pages 2572 - 2579 *
HESPELL ET AL.: "Carbohydrate Metabolism in Spirochaeta stenostrepta", J. BACTERIOL., vol. 103, no. 1, 1970, pages 216 - 226 *
SANDERS: "Rapid escalation characterizes arms race between virus and host", UC NEWSROOM, 22 May 2008 (2008-05-22), BERKELEY, pages 1 - 3, Retrieved from the Internet <URL:httpl/www.universityofcalifornia.edu/news/article/17925> [retrieved on 20100623] *
SHAW ET AL.: "Metabolic engineering of a thermophilic bacterium to produce ethanol at high yield", PROC. NATL. ACAD. SCI. U S A, vol. 105, no. 37, September 2008 (2008-09-01), pages 13769 - 13774 *
TANNLER ET AL.: "'Screening of Bacillus subtilis transposon mutants with altered riboflavin production", METAB. ENG., vol. 10, no. 5, September 2008 (2008-09-01), pages 216 - 226 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400110B2 (en) 2015-05-06 2022-08-02 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US12226430B2 (en) 2015-05-06 2025-02-18 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11844760B2 (en) 2015-05-06 2023-12-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11642363B2 (en) 2015-05-06 2023-05-09 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11547716B2 (en) 2015-05-06 2023-01-10 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11147830B2 (en) 2015-05-06 2021-10-19 Snipr Technologies Limited Altering microbial populations and modifying microbiota
US11471531B2 (en) 2016-06-05 2022-10-18 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10953090B2 (en) 2016-06-05 2021-03-23 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11291723B2 (en) 2016-06-05 2022-04-05 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US12318445B2 (en) 2016-06-05 2025-06-03 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11351252B2 (en) 2016-06-05 2022-06-07 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10765740B2 (en) 2016-06-05 2020-09-08 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US11141481B2 (en) 2016-06-05 2021-10-12 Snipr Technologies Limited Selectively altering microbiota for immune modulation
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US11832598B2 (en) 2016-11-04 2023-12-05 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US11643653B2 (en) 2018-04-30 2023-05-09 Snipr Biome Aps Treating and preventing microbial infections
US11788085B2 (en) 2018-04-30 2023-10-17 Snipr Biome Aps Treating and preventing microbial infections
US10920222B2 (en) 2018-04-30 2021-02-16 Snipr Biome Aps Treating and preventing microbial infections
US11485973B2 (en) 2018-04-30 2022-11-01 Snipr Biome Aps Treating and preventing microbial infections
US11421227B2 (en) 2018-04-30 2022-08-23 Snipr Biome Aps Treating and preventing microbial infections
US12448619B2 (en) 2018-04-30 2025-10-21 Snipr Biome Aps Treating and preventing microbial infections
US12076375B2 (en) 2022-06-29 2024-09-03 Snipr Biome Aps Treating and preventing E coli infections

Also Published As

Publication number Publication date
WO2010075424A2 (fr) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2010075424A3 (fr) Compositions et procédés de réduction de gènes procaryotes
WO2012164565A8 (fr) Compositions et procédés pour la régulation à la baisse de gènes procaryotes
WO2013032850A3 (fr) Compositions et procédés pour un assemblage haute-fidélité d&#39;acides nucléiques
WO2010127304A3 (fr) Procédés de séquençage
WO2008058282A3 (fr) Procédés et compositions pour analyse à grande échelle d&#39;acides nucléiques par suppressions d&#39;adn
WO2008093847A1 (fr) Adn codant pour la xylitol déshydrogénase
CA2884084C (fr) Loci de performance fad2 et proteines se liant a un site specifique cible correspondantes pouvant induire des cassures ciblees
WO2010062480A3 (fr) Procédés et compositions pour la production d&#39;alcools gras
WO2008052101A3 (fr) Ingénierie génomique automatisée à multiplexage
WO2011082425A3 (fr) Variants d&#39;alpha-amylase et polynucleotides les codant
WO2007124285A3 (fr) Polypeptides ayant une activité de glucoamylase et polynucléotides codant pour ceux-ci
NZ601247A (en) Targeted genomic alteration
MX342195B (es) Nucleótidos de terminación de rápida fotodescomposición 5-metoxi, 3&#39; -oh no bloqueados y métodos para secuenciación de ácido nucleico.
WO2010115016A3 (fr) Compositions constituées d&#39;une préparation d&#39;acides nucléiques et procédés associés
WO2010027497A3 (fr) Préparations, compositions et procédés de séquençage d&#39;acides nucléiques
EP3358014A3 (fr) Procédé de stabilisation d&#39;acides nucléiques fonctionnels
WO2006005074A3 (fr) Nouvelle amplification d&#39;acides nucleiques par demarrage a chaud
WO2010042664A3 (fr) Procede et compositions pour produire des aldehydes gras
NZ597299A (en) Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell
WO2014162307A3 (fr) Procédés et appareil utilisables en vue de la synthèse d&#39;acides nucléiques
WO2009060124A3 (fr) Utilisation d&#39;oligonucléotides avec des bases modifiées dans l&#39;hybridation d&#39;acides nucléiques
WO2009105612A3 (fr) Séquences de nucléotides et polypeptides correspondants conférant des caractéristiques d’efficacité d’utilisation de l’azote améliorées dans des végétaux
WO2012078536A3 (fr) Composés oligonucléotidiques à double brin comprenant des modifications de position
WO2010141511A3 (fr) Polynucléotides pour interférence arn multivalente, compositions et procédés pour les utiliser
WO2008067423A3 (fr) Procédé d&#39;amélioration de l&#39;introduction d&#39;adn dans des cellules bactériennes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835782

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09835782

Country of ref document: EP

Kind code of ref document: A2